Publication:
The clinical translational potential of p53-related alterations as cancer biomarkers

Loading...
Thumbnail Image
Date
2015
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Xiao, Meng ; Wang, Xu ; Chen, Wantao
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
10.14670/HH-11-637
item.page.type
info:eu-repo/semantics/article
Description
Abstract
We aimed to analyse and summarise the potential value of the clinical use of p53-related alterations as cancer biomarkers. A systematic search and collection of the published meta-analyses on p53- related alterations and cancers in the past 5 years was conducted through appropriate queries in the PubMed database. We then composed “grey-scale” tables to show the significant levels for each variant, and the potential heterogeneity was subsequently discussed. The data show that p53-related alterations are extremely complex biomarkers in terms of their clinical translation. Together with the experimental studies on p53-related alterations, a gold-standard approach is still in need of development, with more evidence from clinical studies with large, prospectively planned cohorts, to fully understand its potential as a cancer biomarker.
publication.page.subject
Citation
Histology and Histopathology, vol. 30, nº 10, (2015)
item.page.embargo